Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review
Critical Reviews in Oncology/Hematology, 08/08/2012
Ascierto PO et al. – The data suggest greater responses in patients with stage III micro–metastatic versus macro–metastatic disease, and ulceration may also predict greater sensitivity to therapy. Presently, Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) remain valid adjuvant therapies following resection of high–risk melanoma; the most appropriate treatment regimen should be determined on an individual patient basis according to patient lifestyle and approach, potential for toxicity, and the available clinical evidence.
